Progressive €250,000 Parenteral Diet Analysis Grant Awarded by Fresenius Kabi


This year’s winner is a professor Stefan Schaller MD of the Charité – University Medicine Berlin, Germany, for his proposal entitled “Improved muscle metabolism through a combination of muscle activation and protein substitution”. The aim of this state-of-the-art study is to examine the effects of protein substitution before and after early, targeted mobilization in the acute phase of a critical illness. The announcement was made at the congress of the European Society for Clinical Nutrition and Metabolism (ESPEN).

During the virtual award ceremony, Professor Schaller said: “After having worked on this research proposal for a long time, I and my research team are delighted to be able to conduct the study, and I am very grateful for the generous support from Fresenius Kabi. I am very optimistic that this study will have an impact on nutritional therapy in intensive care. “

Professor Schaller took part in the program along with 18 other participants from around the world, including representatives from Africa, Asia, Australia, Europe, New Zealand, and north and South America. After four training units, the participants presented their research proposals to an independent international scientific committee consisting of five field-leading experts: Professor Mette Berger, Switzerland; professor Olav Rooyackers, Sweden; professor Tim peace, Germany; professor Robert Martindale, United States of America; and professor Ho-Seong Han, South Korea. The committee was impressed with the high quality of all proposals, which made choosing a winner very difficult.

Dr. Jos Simons, Executive Vice President of Fresenius Kabi, commented: “We are very pleased to be able to award Professor Schaller this research grant. Both the scientific committee and Fresenius Kabi were surprised by his suggestion and the positive effects. ”On clinical practice. We are very pleased that Professor Schaller can start this clinical study. “

This is the second JUMPstart research grant with 250,000 euros. The first program with 19 participants was launched in 2019 with the grant to nutritionist Lizl Veldsman, Tygerberg Academic Hospital in Cape Town, South Africa.

With the JUMPstart training program and research grant, Fresenius Kabi is supporting the next generation of clinical experts who are contributing to the advancement of nutritional therapy for critically ill patients.

Fresenius Kabi is a global healthcare company specializing in life-saving drugs and technologies for infusions, transfusions and clinical nutrition. The company’s products and services are used to care for critically and chronically ill patients. The Fresenius Kabi product portfolio includes a comprehensive range of IV generics, infusion therapies and products for clinical nutrition as well as the devices for their administration. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, Fresenius Kabi’s first biosimilar product was launched. In the field of transfusion medicine and cell therapy, Fresenius Kabi offers products for extracting blood components and extracorporeal therapies.

With its corporate philosophy “Caring for Life”, the company is committed to putting essential medicines and technologies in the hands of people who help patients and find the best answers to their challenges.

Fresenius Kabi has around 40,500 employees worldwide. In 2020 the company achieved sales of around EUR 7.0 billion. Fresenius Kabi AG is a wholly-owned subsidiary of the health care group Fresenius SE & Co. KGaA.

Further information is available at

This press release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, such as the availability of funding. Fresenius Kabi assumes no responsibility for updating the forward-looking statements in this press release.

Managing directors: Michael Sen (Chairman), Marc Crouton, John Ducker, Dr. Oskar Haszonits, Dr. Christian Hauer, Dr. Michael Schönhofen, Gerrit Steen

Chairman of the supervisory board: Stephan Sturm

Registered office: Bad Homburg, Germany

Commercial Register: Bad Homburg District Court – HRB 11654

Emese Kamp
PINK CARROTS Communications GmbH
E-mail: [email protected]
Phone: +49 69 4272614-141

Photo –
Logo –

SOURCE Fresenius Kabi

similar links